Keysight Receives Frost & Sullivan's 2025 Global Company of the Year Award for 6G Excellence.

Canaccord raises Illumina's (ILMN) price target from $99 to $105 and maintains a Hold rating after the company's Q2 2025 results exceeded estimates and FactSet consensus. The updated target reflects anticipated revenue growth and a slight improvement in operating margins. Illumina's high-throughput technology is crucial for whole-genome sequencing, and its microarrays enable cost-effective genetic screening. The company's revenue over the past year is $4.337 billion, with a recent decline in revenue growth of -4.1% YoY.

Canaccord Genuity analyst Kyle Mikson maintained a Hold rating on Illumina (ILMN) stock while raising the price target from $99 to $105 following the company's Q2 2025 earnings report. The updated target reflects anticipated revenue growth and a slight improvement in operating margins [1].

Illumina reported quarterly earnings of $1.19 per share, beating the analyst consensus estimate of $1.01 per share. The company also posted quarterly sales of $1.059 billion, exceeding the analyst consensus estimate of $1.049 billion. The earnings were driven by the continued ramp in X consumables and accelerating growth in the clinical segment, which is the company's largest customer segment [1].

The company's high-throughput technology is crucial for whole-genome sequencing, and its microarrays enable cost-effective genetic screening. Illumina's revenue over the past year was $4.337 billion, with a recent decline in revenue growth of -4.1% YoY [1].

The stock's post-earnings decline underscores investor skepticism, with ILMN trading 33% below its 52-week high of $156.66, despite a strong EPS beat of 17.8%. The market appears to be pricing in continued pressure from NIH funding uncertainty, competitive threats, and the gradual transition to the NovaSeq X platform [2].

Illumina's 2025 strategy is anchored in transformative technologies poised to redefine the industry, including Constellation Mapped Read Technology, Spatial Transcriptomics, 5-Base Methylation Analysis, and Multiomics Integration. These innovations are supported by strategic acquisitions and partnerships, positioning Illumina to benefit from the $10B+ growth in precision medicine [2].

References:
[1] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46800842/these-analysts-boost-their-forecasts-on-illumina-following-upbeat-results
[2] https://www.ainvest.com/news/illumina-earnings-dilemma-stock-sharp-decline-buying-opportunity-2508/